La cadena de opciones muestra datos clave de las opciones de acciones de Ensysce Biosciences a varios precios de ejercicio y fechas de vencimiento. Los operadores utilizan esta información para analizar posibles operaciones y evaluar el sentimiento del mercado para Ensysce Biosciences..

Ensysce Biosciences (NASDAQ:ENSC) Bolsa, Cadena de Opciones

Ensysce Biosciences

Ensysce Biosciences Inc is a clinical-stage biotech company using its proprietary technology platforms to develop safer prescription drugs. The company is developing a new class of powerful, tamper-proof opioids that prevent both drug abuse and overdoses. Its products are anticipated to provide safer options to treat severe pain and assist in preventing deaths caused by opioid abuse, reducing human and economic costs. The company's current development pipeline includes two new drug platforms: an abuse-resistant opioid prodrug technology, theTrypsin Activated Abuse Protection, or the TAAP platform, and an over-dose protection opioid prodrug technology, the Multi-Pill Abuse Resistant, or the MPAR platform. The Company currently operates in one business segment, which is pharmaceuticals.

Ensysce Biosciences Inc

Ensysce Biosciences Inc Warrants (05/12/2019)

WIIM

RSLS

ReShape Lifesciences shares are trading higher after the company announced a partnership with Motion Informatics to exclusively import and distribute neuromuscular rehabilitation devices in the US.

In a stunning market turnaround, the ProShares UltraPro QQQ (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TQQQ#NASDAQ">TQQQ</a>) soared over 35% on Wednesday afternoon, riding the coattails of a broad tech-driven rally sparked by President Donald Trump's <a href="https://www.benzinga.com/25/04/44720006/markets-take-off-as-trump-announces-90-day-tariff-pause-for-non-retaliating-nations-slaps-china-with-125-duty">90-day tariff pause for non-retaliating nations</a>.
What To Know: TQQQ, which offers triple-leveraged exposure to the Nasdaq-100 Index, benefits disproportionately from sharp moves in large-cap technology stocks. 
The ETF's top holdings mirror those of the Invesco QQQ Trust (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>) and include mega caps like Apple, Microsoft, Nvidia, Amazon and Meta Platforms—all of which <a href="https://www.benzinga.com/economics/macro-economic-events/25/04/44720903/nasdaq-100-eyes-strongest-day-since-2008-as-magnificent-seven-add-15-trillion-in-historic-market-rally">posted double-digit gains </a>Wednesday afternoon.
Investors interpreted the tariff reprieve as a de-escalation of global trade tensions — particularly with key U.S. allies — while simultaneously deepening pressure on China.
Treasury Secretary Scott Bessent's comments provided a policy framework investors embraced: certainty in reciprocal tariffs, punitive measures for China and <a href="https://www.benzinga.com/25/04/44720006/markets-take-off-as-trump-announces-90-day-tariff-pause-for-non-retaliating-nations-slaps-china-with-125-duty">potential for future negotiations</a>.
The Nasdaq-100 meanwhile surged 10%, fueling a risk-on rotation into high-beta names, especially in the technology and consumer discretionary sectors.
The triple-levered ProShares UltraPro QQQ closed Wednesday up 35.2% at $52.61, according to data from <a href="http://pro.benzinga.com">Benzinga Pro</a>.
Read Also: 
<ul>
<li><a href="https://www.benzinga.com/economics/macro-economic-events/25/04/44720903/nasdaq-100-eyes-strongest-day-since-2008-as-magnificent-seven-add-15-trillion-in-historic-market-rally">Nasdaq 100 Set For Strongest Rally Since 2008 As Magnificent 7 Add $1.5 Trillion In Historic Surge</a></li>
</ul>

News

Movers

TQQQ

TQQQ Surges Over 35% In Tech-Led Rebound Following Trump's Tariff Pause

Integration of BD Phoenix&#x2122; Automated Microbiology System, BDXpert&#x2122; System and BD Synapsys&#x2122; Informatics Solution Supports Accurate Detection of Antimicrobial Resistance
FRANKLIN LAKES, N.J. (April 9, 2025) – BD (Becton, Dickinson and Company) (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BDX#NYSE">BDX</a>), a leading global medical technology company, today announced U.S. Food and Drug Administration (FDA) 510(k) clearance for BD Phoenix&#x2122; M50 and BDXpert&#x2122; System on the BD Synapsys&#x2122; Informatics Solution, leveraging rapid identification (ID) and antimicrobial susceptibility testing (AST) algorithms to assist in the interpretation of complex diagnostic data to help ensure accurate and reliable diagnoses related to antimicrobial resistance (AMR).

Biotech

General

BD Receives FDA 510(k) Clearance For Advanced Microbiology Solution

HRZN

Horizon Technology Finance Originates $100.3M Of New Loans In Q1; Ends Quarter With Committed Backlog Of $235.5M

In a stunning U-turn, Goldman Sachs has officially withdrawn its call for an outright U.S. recession, issued just hours before President Donald Trump stunned markets with a surprise announcement of a 90-day tariff pause for countries that have not retaliated <a href="https://www.benzinga.com/topic/tariffs">against U.S. trade measures.</a>
The move underscores the immediate and far-reaching implications of Trump's announcement, which caught Wall Street experts off guard.
&#8220;We are reverting to our previous non-recession baseline forecast, with GDP growth of 0.5% and a 45% probability of recession." Goldman Sachs chief economist Jan Hatzius wrote in a late day note.
Goldman now sees 0.5% U.S. GDP growth in 2025 and a 45% probability of recession—down from the full recession baseline forecast it published earlier that same day.
The bank still expects three 25-basis-point Fed &#8220;insurance cuts&#8221; in June, July and September but sees a less dire macro trajectory, thanks to the tariff pause and signs of trade stabilization.
The revised forecast reflects Trump's differentiated strategy: escalate pressure on China while opening a negotiation path for allies who've held fire.
Trump announced a 10% minimum reciprocal tariff for non-retaliating nations; sector-specific tariffs of up to 25% are still expected. He confirmed that tariffs on Chinese imports will be 125%.
Commerce Secretary Howard Lutnick confirmed the scale of the pivot, writing on X that he and Treasury Secretary Scott Bessent were with Trump as he drafted the announcement, calling it "one of the most extraordinary Truth posts of his presidency."
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">Scott Bessent and I sat with the President while he wrote one of the most extraordinary Truth posts of his Presidency. The world is ready to work with President Trump to fix global trade, and China has chosen the opposite direction. <a href="https://t.co/wNvg8NBnSR">pic.twitter.com/wNvg8NBnSR</a>
&mdash; Howard Lutnick (@howardlutnick) <a href="https://twitter.com/howardlutnick/status/1910022477373227166?ref_src=twsrc%5Etfw">April 9, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
To reporters outside the White House, Trump was blunt. "Somebody had to do it. It had to stop because it's not sustainable. Last year, China made $1 trillion off trade with the United States. Now I've reversed it."
Trump also floated the idea of tariff exemptions for certain U.S. companies and added that "China wants to make a deal.&#8221;
Billionaire hedge fund manager Bill Ackman hailed Trump's maneuver as "brilliantly executed," adding: "Every U.S. company that sources products in China is now finding alternative suppliers. Supply chains are sticky. Tick tock."
<h3 class="wp-block-heading">Markets Soar In Historic Day</h3>
The Dow Jones closed up by nearly 3,000 points to 40,608 points, up 7.9%. 
The S&amp;P 500 – as tracked by the SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) – soared 9.5%, the largest one-day gain since October 2008.
The index surged more than 10% between its intraday low and high—marking the largest single-day swing on record.
The Nasdaq 100 – tracked by the Invesco QQQ Trust (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>) – rocketed 12.2%, also the strongest one-day jump since October 2008. 
<h3 class="wp-block-heading">Magnificent Seven – Daily Gains</h3>
<ul>
<li>NVIDIA Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) surged 18.72%, adding $439.87 billion in market cap, closing at $114.33.</li>
<li>Apple Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>) jumped 15.33%, gaining $397.05 billion, closing at $198.85.</li>
<li>Microsoft Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSFT#NASDAQ">MSFT</a>) rose 10.13%, increasing market value by $267.01 billion, closing at $390.49.</li>
<li>Amazon.com Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>) advanced 11.98%, up $216.66 billion, closing at $191.10.</li>
<li>Meta Platforms Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/META#NASDAQ">META</a>) rallied 14.76%, adding $190.88 billion, closing at $585.77.</li>
<li>Alphabet Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOG#NASDAQ">GOOG</a>) climbed 9.88%, boosting market cap by $175.29 billion, closing at $161.06.</li>
<li>Tesla Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) soared 22.69%, gaining $161.91 billion, finishing at $272.20.</li>
</ul>
Total market cap addition: $1.85 trillion
Read now: 
<ul>
<li><a href="https://www.benzinga.com/economics/macro-economic-events/25/04/44720903/nasdaq-100-eyes-strongest-day-since-2008-as-magnificent-seven-add-15-trillion-in-historic-market-rally">Nasdaq 100 Set For Strongest Rally Since 2008 As Magnificent 7 Add $1.5 Trillion In Historic Surge</a></li>
</ul>
Photo: Shutterstock

Equities

Government

Large Cap

Macro Economic Events

Regulations

Broad U.S. Equity ETFs

Econ #s

Economics

ETFs

AAPL

AMZN

GOOG

MSFT

NVDA

TSLA

Goldman Sachs Scraps Recession Call After Trump's Surprise Tariff Pause As Wall Street Marks Strongest Day Since 2008

SVRA

Savara shares are trading higher after the company announced encore presentations for its Phase 3 IMPALA-2 trial.

Richardson Electronics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RELL#NASDAQ">RELL</a>) reported quarterly earnings of $0.11 per share which beat the analyst consensus estimate of $0.10 by 10 percent. This is a 120 percent increase over earnings of $0.05 per share from the same period last year. The company reported quarterly sales of $53.80 million which missed the analyst consensus estimate of $54.73 million by 1.70 percent. This is a 2.73 percent increase over sales of $52.38 million the same period last year.

Earnings

Earnings Beats

Earnings Misses

RELL

Richardson Electronics Q3 EPS $0.11 Beats $0.10 Estimate, Sales $53.80M Miss $54.73M Estimate

Costco Wholesale Corporation ("Costco" or the "Company") (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COST#NASDAQ">COST</a>) today reported net sales of $25.51 billion for the retail month of March, the five weeks ended April 6, 2025, an increase of 8.6 percent from $23.48 billion last year.
Net sales for the first 31 weeks were $158.87 billion, an increase of 8.3 percent from $146.64 billion last year.
Comparable sales for the periods ended April 6, 2025, were as follows:
<figure class="table"> 
<table>
<tbody>
<tr>
<td>5 Weeks</td>
<td>31 Weeks</td>
<td>&nbsp;</td>
</tr>
<tr>
<td>U.S.</td>
<td>7.5%</td>
<td>7.0%</td>
</tr>
<tr>
<td>Canada</td>
<td>4.1%</td>
<td>4.9%</td>
</tr>
<tr>
<td>Other International</td>
<td>2.9%</td>
<td>3.0%</td>
</tr>
<tr>
<td>Total Company</td>
<td>6.4%</td>
<td>6.1%</td>
</tr>
<tr>
<td>E-commerce</td>
<td>16.2%</td>
<td>16.8%</td>
</tr>
</tbody>
</table>
</figure>
Comparable sales excluding the impacts from changes in gasoline prices and foreign exchange were as follows:
<figure class="table"> 
<table>
<tbody>
<tr>
<td>5 Weeks</td>
<td>31 Weeks</td>
<td>&nbsp;</td>
</tr>
<tr>
<td>U.S.</td>
<td>8.7%</td>
<td>8.0%</td>
</tr>
<tr>
<td>Canada</td>
<td>10.6%</td>
<td>8.9%</td>
</tr>
<tr>
<td>Other International</td>
<td>9.9%</td>
<td>8.9%</td>
</tr>
<tr>
<td>Total Company</td>
<td>9.1%</td>
<td>8.3%</td>
</tr>
<tr>
<td>E-commerce</td>
<td>17.5%</td>
<td>17.7%</td>
</tr>
</tbody>
</table>
</figure>
March had one additional shopping day versus last year, due to the calendar shift of Easter. This positively impacted total and comparable sales by approximately one and one-half percent.
Additional discussion of these results is available in a pre-recorded message. It can be accessed by visiting investor.costco.com (click on "Events &amp; Presentations"). This message will be available through 4:00 p.m. (PT) on Wednesday, April 16, 2025.

COST

Costco Wholesale Reports Net Sales Of $25.51B For The Retail Month Of March, The Five Weeks Ended April 6, 2025, An Increase Of 8.6% From $23.48B Last Year

Contracts

BWXT

BWX Technologies Joint Venture Strategic Storage Partners Awarded Strategic Petroleum Reserve Contract; Estimated Value Of The Contract Is ~$2.6B Over 10 Years

Management

MSGE

MSG Entertainment Appoints David Collins As Executive Vice President And CFO, Effective April 14th

MSBI

Midland States Bancorp Received Nasdaq Deficiency Notice

Amtech Systems, Inc. (&quot;Amtech&quot;) (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASYS#NASDAQ">ASYS</a>), a manufacturer of equipment and consumables for semiconductor fabrication and packaging, provided a business update for the second quarter which ended on March 31st, 2025.
Amtech&#39;s Thermal Processing Solutions Segment experienced a customer dispute during its fiscal second quarter. The dispute involves a previously cancelled order and resulted in the shipping delay of a separate order in the amount of approximately $4.9 million. While the matter is ongoing, the Company believes that the equipment will ship once this matter is resolved. The Company also experienced weaker demand in the Semiconductor Fabrication Solutions Segment during the second quarter due to continued softening of the mature node semiconductor industry, which includes silicon carbide.
As a result of these challenges in the second quarter, the Company now expects second quarter revenues in the range of $15 - $16 million, and nominally negative adjusted EBITDA, compared to the original second quarter guidance of $21 - $23 million revenue and nominally positive adjusted EBITDA. Despite the lower revenues and adjusted EBITDA expected for the second quarter of fiscal 2025, the Company expects to be cash flow neutral.

Guidance

ASYS

Amtech Lowers Q2 Revenue Guidance From $21M-$23M To $15M-$16M

DALLAS, April 09, 2025 (GLOBE NEWSWIRE) -- Capital Southwest Corporation ("Capital Southwest") (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CSWC#NASDAQ">CSWC</a>), an internally managed business development company focused on providing flexible financing solutions to support the acquisition and growth of middle market businesses, today announced an increase to the total commitments under its senior secured credit facility (the "Corporate Credit Facility"). The Corporate Credit Facility was increased under the existing accordion feature by $25 million, bringing total commitments from $485 million to $510 million. The $25 million increase was provided by two existing lenders in the lender group, which consists of 11 participants. The existing accordion feature under the Corporate Credit Facility allows for maximum commitments of up to $750 million.

CSWC

Capital Southwest Increases Corporate Credit Facility to $510M From $485M

<a href="https://www.youtube.com/watch?v=qr9AeMFXzpY" title="https://www.youtube.com/watch?v=qr9AeMFXzpY">https://www.youtube.com/watch?v=qr9AeMFXzpY</a>

Global

Trump Administration Aide Says Trump To Sign Executive Order On Foreign Defense Sales; Trump To Sign Executive Order On Deregulation Of Water Appliances; Canada, Mexico Won't Face 10% Us Tariff

Amtech Systems, Inc. ("Amtech") (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASYS#NASDAQ">ASYS</a>), a manufacturer of equipment and consumables for semiconductor fabrication and packaging, provided a business update for the second quarter which ended on March 31st, 2025.
Amtech's Thermal Processing Solutions Segment experienced a customer dispute during its fiscal second quarter. The dispute involves a previously cancelled order and resulted in the shipping delay of a separate order in the amount of approximately $4.9 million. While the matter is ongoing, the Company believes that the equipment will ship once this matter is resolved. The Company also experienced weaker demand in the Semiconductor Fabrication Solutions Segment during the second quarter due to continued softening of the mature node semiconductor industry, which includes silicon carbide.
As a result of these challenges in the second quarter, the Company now expects second quarter revenues in the range of $15 - $16 million, and nominally negative adjusted EBITDA, compared to the original second quarter guidance of $21 - $23 million revenue and nominally positive adjusted EBITDA. Despite the lower revenues and adjusted EBITDA expected for the second quarter of fiscal 2025, the Company expects to be cash flow neutral.
In addition, due to the prolonged downturn in the mature node semiconductor industry, which includes Silicon Carbide, the Company anticipates a material impairment charge related to goodwill, intangible, and inventory assets in the quarter which ended on March 31, 2025. Due to the complexity and judgement involved in the valuation and impairment analysis, the Company is working with its external advisors to determine the extent of this impairment. The nature and extent of the impairment charge will be communicated during the Company's second quarter earnings call in May.
"We remain encouraged by the strong demand for our advanced packaging reflow equipment, particularly within AI-related applications. Of note, orders for our advanced packaging reflow equipment during the second quarter surpassed shipments for the entire 2024 fiscal year. As we navigate market conditions in the mature node semiconductor industry, we are continuing to actively explore opportunities to further optimize costs and improve efficiency. Despite the near-term challenges, we are confident in the long-term growth potential of Amtech's product portfolio and believe the strong operating leverage resulting from optimization efforts will allow us to deliver enhanced profitability when markets recover," commented Mr. Bob Daigle, Chief Executive Officer of Amtech.
Operating results can be significantly impacted, positively or negatively, by the timing of orders, system shipments, logistical challenges, and the financial results of semiconductor manufacturers. Additionally, the semiconductor equipment industries can be cyclical and inherently impacted by changes in market demand. Actual results may differ materially in the weeks and months ahead.
A portion of Amtech's results is denominated in Renminbis, a Chinese currency. The outlook provided in this press release is based on an assumed exchange rate between the United States Dollar and the Renminbi. Changes in the value of the Renminbi in relation to the United States Dollar could cause actual results to differ from expectations.

Amtech Sees Q2 Revenue $15M-$16M

Project will Deliver Extensive Infrastructure Upgrades across Campus to Ensure Safe and Comfortable Learning Environments while Promoting Sustainability

AMRC

Ameresco Secures $11M Contract With Reed College For Campus Energy Infrastructure Upgrades

MVST

Microvast Holdings Announces Fariyal Khanbabi Steps Down As CFO; Appointed Carl T. Schultz As CFO

Aggregate cash dividend of $69.6 million, or an estimated $2.40 per share
WALTHAM, Mass., April 9, 2025 /PRNewswire/ -- Aerovate Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVTE#NASDAQ">AVTE</a>) ("Aerovate") today announced that its Board of Directors has declared a special cash dividend (the "Cash Dividend") in connection with the previously announced merger (the "Merger") with Jade Biosciences, Inc. ("Jade") pursuant to the Agreement and Plan of Merger, dated October 30, 2024 (the "Merger Agreement"). The Cash Dividend will be an aggregate of $69.6 million, or an estimated $2.40 per share, payable in cash to the stockholders of record as of April 25, 2025. The estimated per share dividend is based on 28,985,019 shares of Aerovate's common stock outstanding as of April 9, 2025. The payment date in respect of the Cash Dividend is scheduled for April 29, 2025.

Dividends

AVTE

Aerovate Therapeutics Declares Special Cash Dividend Of $69.6M, Or An Estimated $2.40 Per Share

XAIR

Beyond Air Releases Article In Annals Of The American Thoracic Society Journal Highlighting NTM-PD Patients' Ability To Safely Self-Administer High-Dose Intermittent iNO Treatments with LungFit GO At Home.

ReShape Lifesciences Agrees with Motion Informatics to Exclusively Import, Distribute AI-Driven Neurorehabilitation Technology to the U.S. Market

Press Releases

Ensysce Biosciences Regains Full Compliance with Nasdaq

Ensysce Biosciences Issues Annual Shareholder Letter

Ensysce Biosciences Announces Positive Interim Data for Breakthrough Therapy PF614-MPAR

Ensysce Biosciences Reports Continued Positive Progress in Groundbreaking Trial on PF614-MPAR, Comments on Current Landscape for Pain Treatment

Entertainment

Ensysce Biosciences CEO Dr. Lynn Kirkpatrick and Creighton University's Dr. Neel Pathak Discuss the Opioid Crisis and Next Generation Opioids

Ensysce Biosciences to Participate in the 37th Annual ROTH Conference

Ensysce Biosciences Reports Fourth Quarter and Full Year 2024 Financial Results

Analyst Ratings

Diamond Equity Research Releases Update Note on Ensysce Biosciences, Inc. (NASDAQ: ENSC)

Ensysce Biosciences Announces PAINWeek 2025 Symposium and Recent Expert Panel Discussion on The State of the Nation in Pain

Ensysce Biosciences, Inc. Announces $1.1 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

Comments

Ensysce Biosciences

Ensysce Biosciences (ENSC) Opciones

No option chain data available. Please try again later

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL